JP2019534003A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534003A5
JP2019534003A5 JP2019521455A JP2019521455A JP2019534003A5 JP 2019534003 A5 JP2019534003 A5 JP 2019534003A5 JP 2019521455 A JP2019521455 A JP 2019521455A JP 2019521455 A JP2019521455 A JP 2019521455A JP 2019534003 A5 JP2019534003 A5 JP 2019534003A5
Authority
JP
Japan
Prior art keywords
seq
adi
nos
antigen
rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019521455A
Other languages
English (en)
Japanese (ja)
Other versions
JP7265984B2 (ja
JP2019534003A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/057708 external-priority patent/WO2018075954A2/en
Publication of JP2019534003A publication Critical patent/JP2019534003A/ja
Publication of JP2019534003A5 publication Critical patent/JP2019534003A5/ja
Priority to JP2022066241A priority Critical patent/JP2022087247A/ja
Application granted granted Critical
Publication of JP7265984B2 publication Critical patent/JP7265984B2/ja
Priority to JP2023146397A priority patent/JP2023158193A/ja
Priority to JP2023146398A priority patent/JP7616813B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019521455A 2016-10-21 2017-10-20 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 Active JP7265984B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022066241A JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146397A JP2023158193A (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146398A JP7616813B2 (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411510P 2016-10-21 2016-10-21
US62/411,510 2016-10-21
PCT/US2017/057708 WO2018075954A2 (en) 2016-10-21 2017-10-20 Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022066241A Division JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Publications (3)

Publication Number Publication Date
JP2019534003A JP2019534003A (ja) 2019-11-28
JP2019534003A5 true JP2019534003A5 (enExample) 2020-11-26
JP7265984B2 JP7265984B2 (ja) 2023-04-27

Family

ID=60263072

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019521455A Active JP7265984B2 (ja) 2016-10-21 2017-10-20 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2022066241A Withdrawn JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146397A Withdrawn JP2023158193A (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146398A Active JP7616813B2 (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022066241A Withdrawn JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146397A Withdrawn JP2023158193A (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146398A Active JP7616813B2 (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Country Status (4)

Country Link
US (3) US11479600B2 (enExample)
EP (1) EP3529272A2 (enExample)
JP (4) JP7265984B2 (enExample)
WO (1) WO2018075954A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201903287PA (en) 2016-10-21 2019-05-30 Adimab Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CA3040893A1 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CN117136197A (zh) * 2021-02-09 2023-11-28 胡默波斯生物医学公司 抗呼吸道合胞病毒、人偏肺病毒和小鼠肺炎病毒的抗体和其使用方法
CN119264248A (zh) * 2022-07-22 2025-01-07 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途
JP2025526405A (ja) * 2022-07-27 2025-08-13 ヒューマブス・バイオメッド・ソシエテ・アノニム Ｒｓｖ及びｍｐｖパラミクソウイルスに対する広域中和抗体
CN119546630A (zh) * 2022-12-08 2025-02-28 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
WO2024259075A1 (en) * 2023-06-14 2024-12-19 Tether Therapeutics, Inc. Polymer formulations for delivery of polynucleotides
WO2025104604A1 (en) * 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
AU686113B2 (en) 1992-09-16 1998-02-05 Scripps Research Institute, The Human neutralizing monoclonal antibodies to respiratory syncytial virus
NZ269735A (en) 1993-07-30 1998-01-26 Oravax Inc Monoclonal iga antibody against respiratory syncytial virus (rsv)
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
EP0853487B1 (en) 1995-09-18 2000-07-05 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
CN1188111C (zh) 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
WO2001064751A2 (en) 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
ATE474854T1 (de) 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6565849B2 (en) 2000-03-02 2003-05-20 Medimmune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
ATE457177T1 (de) 2000-05-03 2010-02-15 Medimmune Llc Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2010081856A1 (en) 2009-01-14 2010-07-22 Ablynx Nv Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
WO2004091519A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7700720B2 (en) 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
JP2008536815A (ja) 2005-03-14 2008-09-11 メディミューン，エルエルシー チオエーテル架橋を含む巨大分子
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2134747A2 (en) 2007-03-06 2009-12-23 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2185590A2 (en) 2007-09-07 2010-05-19 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
WO2009042589A1 (en) 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
KR100938998B1 (ko) 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체
JP5575377B2 (ja) 2008-07-18 2014-08-20 シスメックス株式会社 抗ｒｓウイルスモノクローナル抗体を用いたｒｓウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗ｒｓウイルスモノクローナル抗体
EP2438087B1 (en) 2009-06-05 2017-05-10 Ablynx N.V. Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
US10016496B2 (en) 2013-02-01 2018-07-10 Medimmune, Llc Respiratory syncytial virus F protein epitopes
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US20140323315A1 (en) 2013-04-29 2014-10-30 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
CA2933200C (en) * 2014-01-15 2025-05-06 Medimmune Limited RSV-SPECIFIC ANTIBODIES AND THEIR FUNCTIONAL PARTS
CA2965960A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
CA3040893A1 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201903287PA (en) 2016-10-21 2019-05-30 Adimab Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Similar Documents

Publication Publication Date Title
JP2019534003A5 (enExample)
JP2020518599A5 (enExample)
JP5808536B2 (ja) 抗ｒｓｖｇタンパク質抗体
JP5734988B2 (ja) Ｒｓｖ特異的結合分子
JP2018503361A5 (enExample)
JP2010528601A5 (enExample)
JP2018108086A5 (enExample)
JP2018506966A5 (enExample)
JP2012504955A5 (enExample)
JP2016512554A5 (enExample)
JP2011528902A5 (enExample)
JP2018535650A5 (enExample)
JP2015522252A5 (enExample)
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2022065140A (ja) 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2016503413A5 (enExample)
JP2010516229A5 (enExample)
JP2014524748A5 (enExample)
RU2015136392A (ru) Композиции и способы, основанные на нейтрализующих антителах, доставляемых интраназально, для улучшенной терапевтической эффективности
JP2022087247A (ja) 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2020521797A5 (enExample)
JP2019531293A5 (enExample)
JP2018529661A5 (enExample)
JP2018533569A5 (enExample)
Diethelm-Varela et al. New developments and challenges in antibody-based therapies for the respiratory syncytial virus